Omny-IRE data demonstrated the investigational OMNYPULSETM Platform achieved 100% acute success and 84.5% pulmonary vein isolation (PVI) durabilit ...

PFA is a newer Afib ablation modality touted as reducing the risk of damaging nearby collateral structures, compared with ...

Patients with a high probability of HFpEF may experience greater benefits from atrial fibrillation ablation than those with a ...

Boston Scientific Corporation today announced positive 12-month primary endpoint results from the second phase of the ...

Boston Scientific (BSX) announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial ...

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of ...

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated ...

Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the initiation of the ...

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, announced the continuation of the Quick AF study, which evaluates the investigational ...

One of AI’s most immediate impacts is in screening and identifying patients who may have asymptomatic or paroxysmal AF, those ...

Pulse Biosciences is developing nsPFA technology for cardiac ablation to treat AFib and for ablating benign thyroid nodules.

Aurobindo Pharma Limited has announced that it has received final approval from the US Food & Drug Administration (USFDA) to ...